List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Optimized Dry Powder Formulation and Delivery for Inhaled Clofazimine

    SBC: CREARE LLC            Topic: NIAID

    Treatment regimens for multi drug resistant tuberculosisMDR TBinvolve a spectrum of second tier drugs delivered over a long periodoften over a yearA drug that has shown promise in short regimenssuch as the Bangladesh regimenis oral ClofazimineCFZbut tolerance to oral CFZ is limitedInhaled delivery could potentially limit adverse effects and maximize delivery to the infected pulmonary tissueFormula ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Discovery of novel helminth immunomodulatory proteins for autoimmune diseases

    SBC: CELDARA MEDICAL, LLC            Topic: NIAID

    This contract aims to identify novel parasite derived protein candidates as biologics to treat Crohn s and other diseases with high healthcare costs and no truly long term effective treatment optionsWe will screen stage specific proteins from Onchocerca volvulus that conceivably enable this parasitic helminth to chronically infect the human host by continuously modulating the innate and adaptive i ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. A Preclinical Trial of Therapeutic Angiogenesis Plus Angioplasty and Stenting for Renal Vascular Disease

    SBC: Leflore Technologies LLC            Topic: 400

    Abstract Chronic kidney disease CKD is a progressive disorder affecting almost of the general population and this disease has shown a relentless growth over the past decades Patients with CKD have higher rates of hospitalization greater mortality shorter life expectancy and their healthcare costs are up to times more expensive than non CKD patients Thus treatments to slow halt ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Inhibitors of PSMB and PSMB for the Treatment of Multiple Myeloma

    SBC: InhiProt            Topic: 103

    Multiple myeloma is incurable hematologic malignancy with an expected median survival of years The proteasome inhibitors bortezomib carfilzomib and the recently approved ixazomib are a mainstay of current myeloma treatment Despite an initial response rate approaching to proteasome inhibitor containing combinations all patients relapse and eventually become resistant to any treatments ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration

    SBC: EscaZyme Biochemicals, LLC            Topic: N

    Project Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Developing Testing and Validating a Wearable Alcohol Biosensor

    SBC: Clinitech, LLC            Topic: 450

    PROJECT SUMMARY This application for a Phase I SBIR award represents a collaboration between Clinitech LLC and McLean Hospital Harvard Medical School to develop a wearable biosensor for detecting alcohol in the interstitial fluid of humans who have consumed alcohol Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders including fetal ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Cellular Immunotherapy for SSc

    SBC: CELDARA MEDICAL, LLC            Topic: NIAMS

    Project Summary Systemic sclerosis SSc is a systemic autoimmune disease that results in widespread fibrosis of the skin and internal organs vascular dropout and autoantibody formation SSc has the highest case fatality rate of any systemic autoimmune disease and there remain for FDA approved therapies Analysis of gene expression data on samples collected from SSc patients strongly indicates th ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Complex Dimensional in Vitro Human Skin Tissue Models for Scleroderma

    SBC: CELDARA MEDICAL, LLC            Topic: NIAMS

    Abstract Project Summary Scleroderma Systemic Sclerosis SSc is an autoimmune disease of unknown etiology that is characterized by vascular dysfunction fibrosis and inflammation One in three patients dies within years of diagnosis giving SSc the highest case fatality rate of any systemic autoimmune disease A lack of biologically relevant human SSc disease models has created a critical ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. AUTOMATED PLATE TRANSPORT SYSTEM

    SBC: CREARE LLC            Topic: NIDA

    Contractor will develop a new method of transporting microplates that relies on autonomous quadcopters to move microplates within the laboratory environment Contractor s system incorporates a novel control architecture and copter mounted gripper arm that will provide a cost effective and flexible solution to the problem of automated microplate transport

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic Neutralizing antibodies are not detected in acute phase infection Anti H antibody responses are significantly delayed and exhibit low avidity in comparison with antibodies generated following seas ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government